TSXV · COV.V
Covalon Technologies Ltd.
CA$4.46-CA$0.04 (-0.89%)
Covalon Technologies Ltd.’s quoted price sits in the upper half of its reported 52-week range, 2.83% below the high.
Loading market information…
OTC · PSYBF · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
PsyBio Therapeutics Corp’s quoted price sits in the lower half of its reported 52-week range, 99.8% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow PsyBio Therapeutics Corp’s reporting calendar.
THE COMPANY BEHIND THE TICKER
PsyBio Therapeutics Corp. engages in the development of drugs intended for the treatment of mental health challenges and other disorders. The company was founded on October 28, 2009 and is headquartered in Sunrise, FL.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$4.46-CA$0.04 (-0.89%)
Covalon Technologies Ltd.’s quoted price sits in the upper half of its reported 52-week range, 2.83% below the high.
CA$0.99CA$0.00 (0.0%)
Helix BioPharma Corp.’s quoted price sits in the lower half of its reported 52-week range, 61.92% below the high.
CA$0.81-CA$0.01 (-1.22%)
Arch Biopartners Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.14% below the high.
CHF 0.16+CHF 0.01 (+3.72%)
MindMaze Therapeutics Holding S.A.’s quoted price sits in the lower half of its reported 52-week range, 94.59% below the high.
A$0.08-A$0.01 (-5.62%)
Amplia Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 69.45% below the high.
$0.02+$0.00 (+17.65%)
Oncotelic Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.82% below the high.
$0.03$0.00 (0.0%)
Elixxer Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.12% below the high.
$0.00$0.00 (0.0%)
Sunniva Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
